Celgene (NASDAQ:CELG) was upgraded by Bank of America/Merrill Lynch (NYSE:BAC) to buy from neutral with a price target of $115, as the firm believes that the company can experience compound annual growth of 25% during the next five years.
Shares are higher by over 1.7 percent.
Boston Scientific (NYSE:BSX) was upgraded by Credit Suisse (NYSE:CS) to outperform from neutral with a price target of $7.50 due to improving sales visibility.
Shares are lower by about six tenths of a percent.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.